ArticleBMC medical genomics2025
Development of a prognostic model based on seven mitochondrial autophagy- and ferroptosis-related genes in lung adenocarcinoma.
Article in BMC medical genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung adenocarcinoma (LUAD) is a leading cause of cancer-related mortality globally, necessitating finding novel therapeutic targets. Mitochondrial autophagy (mitophagy) and ferroptosis have emerged as promising avenues in cancer research. This study aimed to identify mitophagy- and ferroptosis-related genes (MiFeRGs) in LUAD and develop a prognostic risk model based on these genes.
methodsIntegration of transcriptomic data from the TCGA dataset with MiFeRG databases was performed. Subsequently, differentially expressed MiFeRGs were identified. A prognostic risk model was developed using univariate, LASSO, and multivariate Cox regression analyses. Survival analysis, immune infiltration assessment, and GSEA analysis were conducted to evaluate the prognostic value and potential mechanisms of MiFeRGs in LUAD. Expression levels and functions of prognostic MiFeRGs were further validated in cells.
resultsA total of 136 differentially expressed MiFeRGs were identified, with enrichment in signaling pathways associated with cancer progression. Seven MiFeRGs (ARPC1A, AURKA, BRD2, HNRNPL, METTL3, NR4A1, and TRPM2) were selected for the prognostic risk model. The model showed wide applicability across various clinical parameters. Furthermore, the PPI network revealed potential associations between MiFeRGs and TCR-related genes, with hub MiFeRG AURKA and TCR-related gene AKT1 having the highest degree values. The levels of AURKA were upregulated in the LUAD cell line and tumor tissues. Moreover, AURKA was associated with mTORC1 activation.
conclusionThe identified MiFeRGs and the developed prognostic risk model provide valuable insights into the molecular mechanisms underlying LUAD progression and offer potential prognostic and therapeutic implications for clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.